Compile Data Set for Download or QSAR
Report error Found 50 Enz. Inhib. hit(s) with all data for entry = 11969
TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667116(US20240116948, Example 10 | 6-(5-chloro-2-fluoroph...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667115(US20240116948, Example 8 | N-{5-[6-(5-chloro-2-flu...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667126(US20240116948, Example 44 | N-{5-[6-(5-chloro-2-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667125(US20240116948, Example 41 | 3-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667124(US20240116948, Example 31 | N-{5-[6-(5-chloro-2-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667123(US20240116948, Example 27 | [3-({5-[6-(5-chloro-2-...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667122(US20240116948, Example 25 | 3-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667121(US20240116948, Example 22 | N-{5-[6-(5-chloro-2-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667120(US20240116948, Example 21 | 5-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667119(US20240116948, Example 18 | N-{5-[6-(5-chloro-2-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667118(US20240116948, Example 17 | N-{5-[6-(5-chloro-2-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667117(US20240116948, Example 12 | N-{5-[6-(5-chloro-2-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667149(US20240116948, Example 45 | N-{5-[6-(5-chloro-2-fl...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667148(US20240116948, Example 43 | 3-[bis(2-hydroxyethyl)...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667147(US20240116948, Example 42 | 3-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667146(US20240116948, Example 40 | Cyclopropyl 5-[6-(5-ch...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667145(US20240116948, Example 38 | N-{5-[6-(5-chloro-2-fl...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667144(US20240116948, Example 37 | 5-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667143(US20240116948, Example 36 | 3-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667142(US20240116948, Example 33 | N-{5-[6-(5-chloro-2-fl...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667141(US20240116948, Example 32 | 5-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667140(US20240116948, Example 30 | 5-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667139(US20240116948, Example 29 | 5-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667137(US20240116948, Example 24 | 2-(dimethylamino)ethyl...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667138(US20240116948, Example 28 | 5-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667127(US20240116948, Example 2 | 4-[6-(5-chloro-2-fluoro...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667128(US20240116948, Example 3 | 4-[6-(6-methylpyridin-2...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667129(US20240116948, Example 4 | 4-[6-(4-methyl-1,3-thia...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667130(US20240116948, Example 5 | 5-[6-(5-chloro-2-fluoro...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667131(US20240116948, Example 6 | 5-[6-(5-chloro-2-fluoro...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667132(US20240116948, Example 9 | N-{5-[6-(5-chloro-2-flu...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667133(US20240116948, Example 16 | N-{5-[6-(5-chloro-2-fl...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667134(US20240116948, Example 19 | Methyl 5-[6-(5-chloro-...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667135(US20240116948, Example 20 | 5-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667136(US20240116948, Example 23 | 5-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667162(US20240116948, Example 48 | Methyl 2-{[2-({5-[6-(5...)
Affinity DataIC50: 7.5nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667151(US20240116948, Example 7 | 5-[6-(5-chloro-2-fluoro...)
Affinity DataIC50: 7.5nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667161(US20240116948, Example 47 | N-{5-[6-(5-chloro-2-fl...)
Affinity DataIC50: 7.5nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667160(US20240116948, Example 46 | N-{5-[6-(5-chloro-2-fl...)
Affinity DataIC50: 7.5nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667159(US20240116948, Example 39 | Methyl 5-[6-(6-methylp...)
Affinity DataIC50: 7.5nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667158(US20240116948, Example 35 | 2-methyl-6-(8-{1H-pyra...)
Affinity DataIC50: 7.5nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667157(US20240116948, Example 34 | 3-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 7.5nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667156(US20240116948, Example 26 | 5-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 7.5nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667155(US20240116948, Example 15 | N-{5-[6-(5-chloro-2-fl...)
Affinity DataIC50: 7.5nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667154(US20240116948, Example 14 | 6-(5-chloro-2-fluoroph...)
Affinity DataIC50: 7.5nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667153(US20240116948, Example 13 | 6-(5-chloro-2-fluoroph...)
Affinity DataIC50: 7.5nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667135(US20240116948, Example 20 | 5-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 7.5nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667150(US20240116948, Example 1 | 3-[6-(5-chloro-2-fluoro...)
Affinity DataIC50: 7.5nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667164(US20240116948, Example C2)
Affinity DataIC50: 1.71E+3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667163(US20240116948, Example C1 | 6-(5-chloro-2-fluoroph...)
Affinity DataIC50: 1.00E+4nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent